Literature DB >> 11741241

Aerosol delivery of muramyl dipeptide to rodent lungs.

R J Pettis1, I Hall, D Costa, A J Hickey.   

Abstract

Tuberculosis is the single most serious infectious disease worldwide. The respiratory tract is the primary site of infection by Mycobacterium tuberculosis(MTB). A number of immunogenic components of the cell wall of MTB, if delivered to the lungs as aerosols, can be used to study the local immune response. The site of deposition of these aerosols can be employed to control their residence time in the lungs. Muramyl dipeptide (MDP) aerosols were delivered to alveolar macrophages in the lungs of rodents. Guinea pig macrophages harvested by bronchoalveolar lavage were examined by differential interference contrast microscopy for morphological changes indicative of activation. Bronchoalveolar lavage fluid was analyzed for the presence of alkaline phosphatase, lactate dehydrogenase, N-acetyl-glucosaminidase (NAG), and total protein content. Rat alveolar macrophages were studied for the production of nitric oxide, by induction of nitric oxide synthase. Twenty-four hours following exposure to an aerosol of MDP, alveolar macrophages exhibited morphological characteristics (spreading and pseudopodia), enzyme activity (NAG 50% above control), and production of the reactive intermediate nitric oxide. Rat macrophages subjected to aerosol exposure to MDP when challenged with a second dose of MDP or lipopolysaccharide exhibited a linear dose response as measured by nitric oxide production. These studies indicate that the topical delivery of an MTB bacterial cell wall component, muramyl dipeptide, results in activation of alveolar macrophages. This approach may be useful in elucidating elements of the immune response to MTB.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11741241      PMCID: PMC2761136          DOI: 10.1208/ps020325

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  8 in total

Review 1.  Systemic macrophage activation with liposome-entrapped immunomodulators for therapy of cancer metastasis.

Authors:  I J Fidler
Journal:  Res Immunol       Date:  1992-02

2.  Potential value of liposomes containing muramyl dipeptide for augmenting the tumoricidal activity of human alveolar macrophages.

Authors:  S Sone; K Tachibana; M Shono; F Ogushi; E Tsubura
Journal:  J Biol Response Mod       Date:  1984

3.  Recombinant human secretory phospholipase A2 released thromboxane from guinea pig bronchoalveolar lavage cells: in vitro and ex vivo evaluation of a novel secretory phospholipase A2 inhibitor.

Authors:  J H Fleisch; C T Armstrong; C R Roman; E D Mihelich; S M Spaethe; W T Jackson; J L Bobbitt; S Draheim; N J Bach; R D Dillard; M Martinelli; R Fouts; D W Snyder
Journal:  J Pharmacol Exp Ther       Date:  1996-07       Impact factor: 4.030

4.  Classification of human colorectal adenocarcinoma cell lines.

Authors:  A Leibovitz; J C Stinson; W B McCombs; C E McCoy; K C Mazur; N D Mabry
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

5.  Serine-protease inhibitors modulate nitric oxide-synthase activity of alveolar macrophages.

Authors:  P G Jorens; F J Van Overeld; H Bult; P A Vermeire; A G Herman
Journal:  Agents Actions       Date:  1992-07

Review 6.  What is nitric oxide and why are so many people studying it?

Authors:  M Gibaldi
Journal:  J Clin Pharmacol       Date:  1993-06       Impact factor: 3.126

7.  Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.

Authors:  N C Phillips; L Chedid; J M Bernard; M Level; P Lefrancier
Journal:  J Biol Response Mod       Date:  1987-12

8.  Activation of macrophage cytostatic and cytotoxic activity in vitro by liposomes containing a new lipophilic muramyl peptide derivative, MDP-L-alanyl-cholesterol (MTP-CHOL).

Authors:  N C Phillips; M L Moras; L Chedid; J F Petit; J P Tenu; E Lederer; J M Bernard; P Lefrancier
Journal:  J Biol Response Mod       Date:  1985-10
  8 in total
  3 in total

1.  Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.

Authors:  Susanne R Youngren-Ortiz; Nishant S Gandhi; Laura España-Serrano; Mahavir B Chougule
Journal:  Kona       Date:  2015-09-30       Impact factor: 2.897

2.  Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines.

Authors:  Chenchen Wang; Pavan Muttil; Dongmei Lu; Adela Ayulia Beltran-Torres; Lucila Garcia-Contreras; Anthony J Hickey
Journal:  AAPS J       Date:  2009-03-10       Impact factor: 4.009

3.  Roles of Mucosal Immunity against Mycobacterium tuberculosis Infection.

Authors:  Wu Li; Guangcun Deng; Min Li; Xiaoming Liu; Yujiong Wang
Journal:  Tuberc Res Treat       Date:  2012-11-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.